clinical trial · NCT05130463
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim·—·completed·n = 1,053
Diabetes Mellitus, Type 2Empagliflozin/Linagliptin
brief summary
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
started
Mar 22, 2022
primary completion
Apr 8, 2024
completion
Jul 8, 2024
last updated
Aug 27, 2025
official title
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol